Homing peptides as targeted delivery vehicles

Print
Published on Friday, 08 September 2017

Abstract

Each normal organ and pathological condition appear to contain organ- or disease-specific molecular tags on its vasculature, which constitute a vascular "zip code" system.

In vivo phage display has been exploited to profile this vascular heterogeneity and a number of peptides that home specifically to various normal organs or pathological conditions have been identified.

These peptides have been used for targeted delivery of oligonucleotides, drugs, imaging agents, inorganic nanoparticles, liposomes, and viruses.

Identification of the receptor molecules for the homing peptides has revealed novel biomarkers for target organs.

In tumors many of these receptors seem to play a functional role in tumor angiogenesis.

Recently, tumor homing peptides have entered clinical trials.

Results from several Phase I and II trials have been reported, and a number of trials are currently ongoing or recruiting patients.

In these trials no dose-limiting toxicity has occurred and all combinations of peptide-targeted therapies have been well tolerated.

 

 

About this publication.

 

See also:

- Somatostatin in oncology, the overlooked evidences;

- Congenital fibrosarcoma in complete remission with Somatostatin, Retinoids, Vitamin D3, Vitamin E, Vitamin C, Melatonin, Calcium, Chondroitin sulfate associated with low doses of Cyclophosphamide in a 14-year Follow Up;

- The Di Bella Method (DBM) in the treatment of prostate cancer: a preliminary retrospective study of 16 patients and a review of the literature;

- Pancreatic Adenocarcinoma: clinical records on 17 patients treated with Di Bella's Method;

- The Di Bella Method Increases by the 30% the survival rate for Pancreas tumors and for this reason should be proposed as first line therapy for this type of cancer;

- Neuroblastoma: Complete objective response to biological treatment;

- Somatostatin, retinoids, melatonin, vitamin D, bromocriptine, and cyclophosphamide in advanced non-small-cell lung cancer patients with low performance status;

- Somatostatin, retinoids, melatonin, vitamin D, bromocriptine, and cyclophosphamide in chemotherapy-pretreated patients with advanced lung adenocarcinoma and low performance status;

- Observations on the Report of a case of pulmonary adenocarcinoma with lymph node, hepatic and osseus metastasis;

- Chronic Lymphocytic Leukemia: Long-Lasting Remission with Combination of Cyclophosphamide, Somatostatin, Bromocriptine, Retinoids, Melatonin, and ACTH;

- Recurrent Glioblastoma Multiforme (grade IV – WHO 2007): a case of complete objective response achieved by means of the concomitant administration of Somatostatin and Octreotide – Retinoids – Vitamin E – Vitamin D3 – Vitamin C – Melatonin – D2 R agonists (Di Bella Method – DBM) associated with Temozolomide;

- Evaluation of the safety and efficacy of the first-line treatment with somatostatin combined with melatonisn, retinoids, vitamin D3, and low doses of cyclophosphamide in 20 cases of breast cancer: a preliminary report;

- The Di Bella Method (DBM) improved survival, objective response and performance status in a retrospective observational clinical study on 122 cases of breast cancer;

- Complete objective response to biological therapy of plurifocal breast carcinoma.